Welcome to the Podiatry Arena forums

You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members, upload content, view attachments, receive a weekly email update of new discussions, access other special features. Registered users do not get displayed the advertisements in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!

  1. Have you considered the Clinical Biomechanics Boot Camp Online, for taking it to the next level? See here for more.
    Dismiss Notice
Dismiss Notice
Have you considered the Clinical Biomechanics Boot Camp Online, for taking it to the next level? See here for more.
Dismiss Notice
Have you liked us on Facebook to get our updates? Please do. Click here for our Facebook page.
Dismiss Notice
Do you get the weekly newsletter that Podiatry Arena sends out to update everybody? If not, click here to organise this.

Melanoma of the foot

Discussion in 'General Issues and Discussion Forum' started by NewsBot, Oct 30, 2009.

  1. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Establishment of a prognostic model for melanoma based on necroptosis-related genes
    Xiaohui Sui et al
    Funct Integr Genomics. 2023 Jun 14;23(3):202
     
  2. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Metastatic melanoma to the proximal ureter
    Matthew DeSanto et al
    Urol Case Rep. 2023 Aug 24;
     
  3. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    The Value of Anterolateral Thigh Free Flap for the Reconstruction of Malignant Melanoma of the Sole of the Foot
    Yong Chan Bae, Joo Hyoung Kim, Changryul Claud Yi
    Ann Plast Surg. 2024 Jan 9
     
  4. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    High prevalence of dermatophytosis of the feet in acral melanoma of the foot
    Yuma Waki et al
    J Dermatol. 2024 May 6
     
  5. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Misdiagnosis and Clinical Insights into Acral Amelanotic Melanoma-A Systematic Review
    Fortunato Cassalia et al
    J Pers Med. 2024 May 13;14(5):518
     
  6. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Study of risk factors for the presence of interdigital nevi of the feet
    V Sánchez-García et al
    Actas Dermosifiliogr. 2024 May 20:
     
  7. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Pattern Analysis of Benign and Malignant Atypical Melanocytic Skin Lesions of Palms and Soles: Variations of Dermoscopic Features According to Anatomic Site and Personal Experience
    Linda Tognetti et al
    Life (Basel). 2024 May 22;14(6):659
     
  8. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    NEWS RELEASE 27-JUN-2024
    The mechanism behind melanoma resistance to treatment
    In many cases of malignant melanoma, the effect of targeted treatment is lost over time. A research team from UZH and USZ has now discovered that a factor secreted by tumor cells is responsible for the resistance. These findings could pave the way for more effective therapies.

    Malignant melanoma is one of the most aggressive types of cancer. Despite recent progress in effective therapies, the tumors of many patients are either resistant from the outset or become so during the course of treatment.

    “It is therefore crucial to understand the mechanism behind resistance development in melanoma,” says Lukas Sommer, professor of stem cell biology at the Institute of Anatomy at the University of Zurich (UZH). A study under his lead has now identified a mechanism that impedes the effectiveness of therapies. The result provides new ideas for treatments to suppress the development of resistance. The project was carried out in collaboration with Mitch Levesque and Reinhard Dummer from the University Hospital Zurich (USZ).

    Comparing resistant and non-resistant tumor cells

    For the study, the team utilized an innovative fine-needle biopsy to sample tumor cells before and during therapy. This allowed the researchers to analyze each cell individually. The patients providing the samples were undergoing targeted cancer therapy for malignant melanoma, which inhibits signalling pathways for tumor formation.

    “It was important that some of the tumors responded to the therapy, while others showed resistance,” says Sommer. This allowed the team to compare the metabolism and environment of resistant and non-resistant tumor cells and look for significant differences.

    Interaction between tumor factor and immune cells

    One of the most relevant findings concerned the POSTN gene: it codes for a secreted factor that plays an important role in resistant tumors. In fact, the tumors of patients with rapidly progressing disease despite treatment showed increased POSTN levels. In addition, the microenvironment of these tumors contained a larger number of a certain type of macrophage – a subtype of immune cell that promotes the development of cancer.

    Through a series of further experiments – both with human cancer cells and with mice – the research team was able to show how the interaction of increased POSTN levels and this type of macrophage triggers resistance: the POSTN factor binds to receptors on the surface of the macrophages and polarizes them to protect melanoma cells from cell death. “This is why the targeted therapy no longer works,” says Sommer.

    No resistance without cancer-promoting macrophages

    The team considers this mechanism a promising starting point. “The study highlights the potential of targeting specific types of macrophages within the tumor microenvironment to overcome resistance,” says Sommer. “In combination with already known therapies, this could significantly improve the success of treatment for patients with malignant melanoma.”
     
  9. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Misdiagnosis and Clinical Insights into Acral Amelanotic Melanoma—A Systematic Review
    Fortunato Cassalia et al
    J. Pers. Med. 2024, 14(5), 518; https://doi.org/10.3390/jpm14050518
     
Loading...

Share This Page